Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00462
|
|||||
| Drug Name |
Olanzapine
|
|||||
| Synonyms |
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; ALKS-7921; Eli Lilly brand of olanzapine; KS-1090; LY 170053; LY-170052; LY-170053; Lanzac; Lilly brand of olanzapine; Midax; Olansek; Olanzapina; Olanzapine (JAN/USAN/INN); Olanzapine (OLA); Olanzapine [USAN:INN]; Olanzapinum; Olzapin (TN); Rexapin (TN); Symbyax; Zalasta; Zalasta (TN); Zolafren (TN); Zydis; Zydis (TN); Zyprexa; Zyprexa (TN); Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Bipolar disorder [ICD11: 6A60-6A61] | Approved | [1] | ||||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H20N4S
|
|||||
| Canonical SMILES |
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
|
|||||
| InChI |
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
|
|||||
| InChIKey |
KVWDHTXUZHCGIO-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 132539-06-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 312.4 | Topological Polar Surface Area | 59.1 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103195217
, 103950390
, 104253651
, 104306829
, 11528747
, 12014657
, 14923451
, 25819934
, 26612730
, 26719852
, 26750094
, 29215187
, 29215188
, 29223674
, 42684855
, 46386668
, 46507666
, 48416347
, 49665994
, 49666419
, 49681733
, 49830782
, 5025348
, 53788662
, 56310909
, 56312010
, 56312820
, 56352944
, 57288797
, 57322337
, 591970
, 77029366
, 7847520
, 7980183
, 81092909
, 816938
, 85174531
, 85209215
, 85213702
, 85753333
, 89736112
, 92307994
, 92308375
, 92308920
, 92712529
, 93166490
, 93167156
, 93618268
, 9530
, 99637141
|
|||||
| ChEBI ID |
ChEBI:7735
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 8.3 microM | Baculovirus-infected insect cells-MDR1 | [3] | |
| References | ||||||
| 1 | Olanzapine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
| 3 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.